|
||||||||||||
 |
||||||||||||
|
||||||||||||
Top Stories
Immunize.org Pages and Handouts
Vaccine Information Statements
Featured Resources
Notable Publications
Upcoming Events
CDC releases new COVID-19 mRNA VIS and updated respiratory syncytial virus (RSV) VIS for individuals who are pregnant or age 60 and older
Immunize.org posted two new Vaccine Information Statements (VISs), published by CDC.
  Immunize.org updated its corresponding reference documents related to the use of VISs:
Related Links
With special support from CDC, Immunize.org recently launched a series of short videos to introduce you to different ways to improve the vaccination experience for infants, children, teens, and adults. Each video is closed captioned and runs 4 minutes or less. Three are for a general audience, and three are specifically intended for healthcare professionals.
Immunize.org posts new Spanish translation of the popular handout "Tips for Locating Old Immunization Records"
For the first time, Immunize.org created and posted a Spanish translation of its helpful and popular document for families, titled Tips for Locating Old Immunization Records.
“Use Same Brand of MenB for All Doses”: watch the 2-minute answer, part of the Ask the Experts Video Series on Facebook, LinkedIn, X (Twitter), YouTube, and Instagram
Immunize.org's social media channels make it easy for you to learn a little more every day. This week, our featured episode from the Ask the Experts Video Series is Use Same Brand of MenB for All Doses. This is available on our YouTube channel, along with our full collection of quick video answers to popular Ask the Experts questions. Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
Track the activity of respiratory viruses this season: use CDC’s FluView and RESP-NET surveillance reports, updated weekly
Influenza, respiratory syncytial virus (RSV), and COVID-19 are circulating at low levels, and CDC expects respiratory virus activity to increase. Influenza activity is currently low nationally with small increases reported in some parts of the country. CDC’s Weekly U.S. Influenza Surveillance Report, FluView, provides a valuable snapshot of influenza activity state-by-state. CDC's Weekly Flu Vaccination Dashboard data show that 116 million doses of influenza vaccine were shipped within the United States through September 30, 2023. CDC recommends everyone age 6 months and older get annual influenza vaccination. Influenza and other vaccines (e.g., COVID-19 vaccine, RSV vaccine) may be given at the same visit, if needed. Locate influenza and COVID-19 vaccines in your area by entering your zip code in the VaccineFinder on Vaccines.gov or Vacunas.gov. To be listed as a provider by VaccineFinder, see the information on this website. Related Links
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Immunize.org updates screening checklists for 2023–24 influenza vaccines in English and Spanish
After receiving questions concerning egg allergy and influenza vaccination, Immunize.org revised the wording of its screening checklists for the 2023–24 influenza season to simplify and clarify the statement that egg allergy of any severity is neither a contraindication nor a precaution to the use of any influenza vaccine.
 
See all the Immunize.org screening checklists by going to the Screening Checklists about Vaccine Contraindications and Precautions main page. Update your screening checklists today.  Related Links
Immunize.org recently updated its resource for the public: Influenza: Questions and Answers. The document now includes updated information for the 2023–24 influenza season. Related Links
Back to top
Immunize.org updated Standing Orders for Administering Hepatitis B Vaccine to Adults. Changes include new information about routine serologic testing for hepatitis B in adults, and a clarification about vaccine brand options and dose intervals for people whose first dose was of an unknown brand. 
Related Links
Recap: Immunize.org retires four of its resources summarizing recommendations and contraindications
After many years as valuable and popular references, Immunize.org retired four of its more than 230 resources for healthcare professionals. The CDC child/adolescent and adult recommended immunization schedules now incorporate detailed clinical notes and list the contraindications and precautions for vaccines on the schedule. In addition, CDC schedules are now updated online more frequently, as new ACIP recommendations and changes to the schedules are made. As a result, the following Immunize.org documents were retired as redundant and users are referred to the CDC schedules for the information:
Immunize.org remains focused on connecting healthcare professionals with the resources you need to achieve excellence in your immunization practice.
Recap: CDC releases new Immunization Information Statement (IIS) (a VIS-like document) for Respiratory Syncytial Virus (RSV) Preventive Antibody (nirsevimab)
On September 25, CDC released a new Immunization Information Statement (IIS) (similar in format to a Vaccine Information Statement [VIS]), for Respiratory Syncytial Virus (RSV) Preventive Antibody (nirsevimab). This IIS document contains important information about the new preventive antibody product for families. Access the IIS in PDF or RTF file (for use in electronic systems).  At this time, the RSV preventive antibody is not part of the Vaccine Injury Compensation Program (VICP); therefore, use of the IIS is not required by federal law. However, as a condition of participating in the Vaccines for Children (VFC) program, providers must give the IIS to parents in the same way that a VIS is provided. Related Links
Back to top
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
 Related Links
Confirm that your VISs are up to date: Immunize.org updates “You Must Provide Patients with Vaccine Information Statements (VISs) – It’s Federal Law!” and “Dates of Current Vaccine Information Statements (VISs)” In response to the Vaccine Information Statements (VISs) released by CDC on October 19, Immunize.org updated its two provider resources about VISs with the publication date of the new Respiratory Syncytial Virus (RSV) Vaccine VIS and updated COVID-19 Vaccine VIS.
  Related Links
CDC posts adorable "Wild to Mild" social media images to promote influenza vaccination
CDC's Wild to Mild social media images are a lighthearted way to promote influenza vaccination. Encourage your patients, friends, loved ones, and followers on social media to get themselves and their families an annual influenza vaccine with the resources below. CDC's toolkit will be updated soon to include customizable graphic frames you can add to your photos, sample social media graphics, and printable materials. HPV vaccine starting at age 9 years: Human Vaccines and Immunotherapeutics publishes 18-article collection on this approach
Despite the effectiveness of HPV vaccination at preventing HPV-related cancers and other diseases, HPV vaccination rates in the United States lag those for other adolescent vaccinations. Starting HPV vaccination at age 9 or 10 years might improve vaccination uptake and increase the number of adolescents who complete their series on time. “SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020–2022” published in Emerging Infectious Diseases
In the October issue, Emerging Infectious Diseases published SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020–2022. A portion of the abstract appears below. To determine whether HIV infection was associated with increased risk for SARS-CoV-2 reinfection, we followed adult residents of Chicago, Illinois, USA, with SARS-CoV-2 longitudinally from their first reported infection through May 31, 2022. . . . Among 453,587 Chicago residents with SARS-CoV-2, a total of 5% experienced a SARS-CoV-2 reinfection, including 192/2,886 (7%) PWH [Persons with HIV] and 23,642/450,701 (5%) persons without HIV [PWOH]. We observed higher SARS-CoV-2 reinfection incidence rates among PWH (66 [95% CI 57–77] cases/1,000 person-years) than PWOH (50 [95% CI 49–51] cases/1,000 person-years). PWH had a higher adjusted rate of SARS-CoV-2 reinfection (1.46, 95% CI 1.27–1.68) than those without HIV. PWH should follow the recommended COVID-19 vaccine schedule, including booster doses. Today! Virtual: Watch October 25–26 ACIP meeting. Topics include immunization schedules and seven vaccine-preventable diseases.
CDC will convene a 2-day meeting of the Advisory Committee on Immunization Practices (ACIP) today, October 25, starting at 8:00 a.m. (ET). ACIP will discuss child and adolescent immunization schedules, adult immunization schedule, influenza, chikungunya, COVID–19, meningococcal, mpox, and pneumococcal vaccines, as well as RSV vaccines for older adults. Votes on immunization schedules, meningococcal vaccines, and mpox vaccine are scheduled.
Virtual: The National Foundation for Infectious Diseases (NFID) hosts webinar titled “Immunization Recommendations during Pregnancy” on November 2 at 12:00 p.m. (ET)
The National Foundation of Infectious Diseases (NFID) will host a webinar titled Immunization Recommendations during Pregnancy, 12:00–1:15 p.m. (ET) on November 2. This interactive panel, featuring experts from the NFID, American College of Obstetricians and Gynecologists (ACOG), and Society for Maternal-Fetal Medicine (SMFM), will include a discussion on recommended vaccination during pregnancy. Speakers will discuss Tdap, COVID-19, influenza, and recent updates in respiratory syncytial virus (RSV) immunization recommendations. There is no fee to participate in this activity, but preregistration is required. For more upcoming events, visit our Calendar of Events.
|
||||||||||||
|
